PETV — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-14

• In August 2021, we received net proceeds of approximately $9.7 million in a registered public offering (“Public Offering”) of 2.5 million units at a public offering price of $4.50 per unit. Each unit consisted of one share of our common stock and one warrant to purchase one share of our common stock…

• The Company was incorporated in March 2009 under Nevada law. The Company operates as one segment from its corporate headquarters in Edina, Minnesota.

• Our initial product, Spryng® is a veterinary medical device designed and engineered to provide a bio-integrative scaffold in the affected joint, promoting restoration of proper joint mechanics. Spryng® is an intra-articular injectable product of biocompatible and insoluble particles that are slipper…

• In December 2023, the Company and MWI agreed to change the Distribution Agreement from an exclusive distribution agreement to a non-exclusive distribution agreement, effective as of January 1, 2024. This is consistent with the Company’s strategy to create multiple sales channels for its products. In…

• In December 2024, we entered into new wholesale distribution partnerships with Vedco Inc. (“Vedco”) and Clipper Distributing, LLC (“Clipper”), both leaders in logistical solutions and supply of products to veterinarians through the channel-of-distribution for veterinarians. Both MWI and Covetrus hav…

Text removed vs the prior filing · source: 10-Q · 2026-02-17

• The Company was incorporated in March 2009 under Nevada law under a different name. The Company operates as one segment from its corporate headquarters in Edina, Minnesota.

• Our initial product, Spryng®, is a veterinary medical device designed to help reinforce and/or augment articular cartilage tissue for the management of lameness and other joint related afflictions, such as osteoarthritis, in horses and companion animals. Spryng® is an intra-articular injectable prod…

• On February 14, 2025, the “Company” and VetStem, Inc. (“VetStem”) entered into an Exclusive License and Supply Agreement pursuant to which VetStem will license to us, on an exclusive basis, the right to sell, have sold, offer for sale and import Therapeutic Compositions and Products involving Precis…

• VetStem, Inc. is a veterinarian-led company established in 2002 to bring regenerative medicine to the veterinary profession. Based near San Diego, California, this privately held biopharmaceutical enterprise offers veterinarians a range of regenerative modalities, including autologous stem cell proc…

• PrecisePRP™ is a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. It is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs …

Text added vs the prior filing · source: 10-Q · 2026-08-14

• Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting as defined in Rule 13a-15(f) and 15d-15(f) promulgated under the Securities Exchange Act of 1934. Our internal control over financial reporting…

• ● Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

• ● Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our…

• ● Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

• Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems if determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections …

Text removed vs the prior filing · source: 10-Q · 2026-02-17

• Other than the ongoing remediation efforts described above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), during the quarter ended December 31, 2025, that have materially affected, or are reasonably likely…

• Based on our assessment, our management concluded that as of December 31, 2025, our internal control over financial reporting was not effective.

Text added vs the prior filing · source: 10-Q · 2026-08-14

• From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. In June 2026, a former employee filed a whistleblower retaliation complaint with the Occupational Safety and Health Administration (OSHA) under Sarbanes-Oxley Act (SOX), 18 U.S.C. § 1514A.…

• The Company is cooperating with OSHA’s ongoing investigation, denies all allegations and intends to vigorously defend against these allegations. At this preliminary stage, the outcome is uncertain. Although the Company cannot predict the ultimate outcome of this matter, based on currently available …

Text removed vs the prior filing · source: 10-Q · 2026-02-17

• From time to time, we may become involved in legal proceedings arising in the ordinary course of our business, the resolution of which we do not anticipate would have, individually or in the aggregate, a material adverse effect on our business, financial condition, or results of operations.

• Refer to Note 11 Commitments and Contingencies, in the Notes to Condensed Consolidated Financial Statements set forth in Part I, Item 1 Financial Statements of this Quarterly Report, for further information regarding legal contingencies.

Text added vs the prior filing · source: 10-Q · 2026-08-14

• In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors discussed in Part I, Item 1A Risk Factors in our Annual Report on Form 10-K for our fiscal year ended March 31, 2026. As of this Quarterly Report, our continued negotiations with VetSte…

Text removed vs the prior filing · source: 10-Q · 2026-02-17

• Our business, financial condition, results of operations, and stock price could be materially and adversely affected by a U.S. federal government shutdown or a sustained period of economic disruption.

• The government shutdown could impact our business in several ways, including, but not limited to the following:

• ○ Reduced Spending: The shutdown may lead to reduced government activity and decreased discretionary spending, which could negatively affect the market for our products and services, particularly if the shutdown is prolonged.

• ○ Supply Chain Disruptions: We may experience disruptions in our supply chain if federal agencies that are critical to the import or export of our goods are affected by the shutdown.

• ○ Limited Access to Capital Markets: An extended SEC shutdown could impact our access to capital markets. While the EDGAR system remains operational, the SEC will not be able to review or accelerate registration statements during a shutdown, which could create challenges if we need to raise capital.